The domestic pharmaceutical industry will have no choice but to increase prices of products meant for the US market if the Trump administration goes ahead...
Pharmaceutical firms are expected to post 11 per cent year-on-year growth in both sales and EBITDA for the first quarter of Financial Year 2026 (Q1FY26),...
The tariffs from the US could severely affect Indian drug manufacturers as the duties would result in higher production costs and make shipments less competitive...
